Who are transdermal clonidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dexmedetomidine 0.25 µg/kg IV, perineural dexmedetomidine, alpha methyldopa, Mirtazapine Tablets, clonidine (drug) intravenously, dexmedetomidine (IN).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/transdermal-clonidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

transdermal clonidine — Competitive Intelligence Brief

transdermal clonidine (transdermal clonidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Cardiovascular.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

transdermal clonidine (transdermal clonidine) — Peking University People's Hospital. Transdermal clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
transdermal clonidine TARGET	transdermal clonidine	Peking University People's Hospital	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
dexmedetomidine 0.25 µg/kg IV	dexmedetomidine 0.25 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
perineural dexmedetomidine	perineural dexmedetomidine	Guangzhou Women and Children's Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
alpha methyldopa	alpha methyldopa	Radboud University Medical Center	marketed	Central-acting alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Mirtazapine Tablets	Mirtazapine Tablets	National Institute of Mental Health, Dhaka	marketed	Tetracyclic antidepressant	Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
clonidine (drug) intravenously	clonidine (drug) intravenously	Medical University of Vienna	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
dexmedetomidine (IN)	dexmedetomidine (IN)	Azienda Ospedaliera di Padova	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). transdermal clonidine — Competitive Intelligence Brief. https://druglandscape.com/ci/transdermal-clonidine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab